Evidence map›Paper›PMID 40772791›Full record

ArticleAging2025

Age-related trends in amyloid positivity in Parkinson's disease without dementia.

Keiko Hatano, Masashi Kameyama, Masanori Kurihara, Kensuke Ohse, Ryoji Goto, Ryoko Ihara, Mana Higashihara, Renpei Sengoku, Yasushi Nishina, Kazutomi Kanemaru and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Keiko HatanoDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Masashi KameyamaAI and Theoretical Image Processing, Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Masanori KuriharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Kensuke OhseIntegrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Ryoji GotoDepartment of Neurology, The University of Tokyo Hospital, Tokyo, Japan.
Ryoko IharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Mana HigashiharaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Renpei SengokuDepartment of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Yasushi NishinaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Kazutomi KanemaruDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Yuko SaitoDepartment of Neuropathology (The Brain Bank for Aging Research), Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Shigeo MurayamaDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Atsushi IwataDepartment of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid-beta (Aβ) plays a pivotal role in cognitive decline in Parkinson's disease (PD). The prevalence of amyloid positivity, evaluated using the cerebrospinal fluid (CSF) of patients with PD without dementia in their sixties, is lower than that in individuals with normal cognition without PD diagnosis in the same age range. However, it is unclear whether this is also the case in patients with PD without dementia in their eighties. Eighty-nine patients with PD without dementia were retrospectively classified into two groups with a cut-off age of 73 years at diagnosis: a HIGH group and a LOW group, with mean age at diagnosis of 80.2 and 64.9 years, respectively. The prevalence of amyloid positivity was significantly higher in the HIGH (30.6%) than in the LOW group (10.0%) (

Indexed as

AgingAmyloid beta-PeptidesParkinson DiseaseAgedAged, 80 and overAge FactorsDementiaFemaleHumansMaleMiddle AgedRetrospective StudiesAmyloid beta-Peptidesamyloid positivitycerebrospinal fluid Aβ42Parkinson's disease without dementia

Identifiers

PMID40772791
PMCPMC12422822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.